STOCK TITAN

Morphic Holding Inc - MORF STOCK NEWS

Welcome to our dedicated news page for Morphic Holding (Ticker: MORF), a resource for investors and traders seeking the latest updates and insights on Morphic Holding.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Morphic Holding's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Morphic Holding's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.28%
Tags
conferences clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.1%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.49%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.15%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.05%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.58%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.77%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
none
Morphic Holding Inc

Nasdaq:MORF

MORF Rankings

MORF Stock Data

1.43B
36.79M
16.78%
91.49%
11.8%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Waltham

About MORF

oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. morphic tx is joining a three decade quest led by our scientific founder, tim springer, who initially discovered the integrin receptor family in the 1980s. this receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, crohn's disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention. despite blockbuster commercial success, integrins have remained out of reach as small molecule drugs...until now.